E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Type 2 Diabetes Mellitus and Renal Impairment |
|
E.1.1.1 | Medical condition in easily understood language |
diabetes and chronic kidney disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067585 |
E.1.2 | Term | Type 2 diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate non-inferiority (with a margin of 0.3%) and, if achieved, to demonstrate the superiority in the efficacy of Gla-300 compared with IDeg-100 in terms of change in HbA1c from baseline to Week 24 in insulin-naïve patients with T2DM and renal impairment who have glycemic levels above target with oral antidiabetic drugs (OADs) with or without glucagon-like peptide 1 receptor agonist (GLP-1 RA) |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effects of treatment with Gla-300 compared with IDeg-100 on clinical parameters. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Continuous glucose monitoring (CGM) sub-study. The CGM sub-study (applicable only to North American sites) will run concurrently with the main trial, and patients eligible for the CGM sub-study will have 2 additional site visits at Week 14 and Week 22.
A sub-study will be conducted to evaluate the effects of treatment with Gla-300 compared with IDeg-100 on metrics derived from blinded continuous glucose monitoring (CGM) at Week 12 and Week 24 in patients with T2DM and renal impairment.
|
|
E.3 | Principal inclusion criteria |
Each patient must meet all of the following criteria to be enrolled in this trial: 1. Is an adult aged ≥18 years at screening. 2. Was diagnosed with T2DM of >1-year duration and had glycemic levels above target with OADs with or without GLP-1 RA (oral or injectable) at stable doses for ≥3 months before the screening period. 3. Has an HbA1c ≥7.5% and ≤10.5% at screening. 4. Has renal impairment, as defined by an eGFR of <60 mL/min/1.73m2 and ≥15 mL/min/1.73m2 (using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation; National Kidney Foundation 2022). 5. Has adequately controlled blood pressure with stable antihypertensive therapy at trial inclusion. 6. Is insulin-naïve, except for short use of insulin not exceeding 15 days during the last year before the screening period. 7. Is capable of understanding the written informed consent, and provides signed written informed consent. 8. Is willing and able to complete the electronic diary (eDiary) and agrees to comply with protocol requirements. 9. Is willing and able to fast without having administered study drug for scheduled site visits. (Note: Fasting is defined as no intake of food or drink, except water, in the 8 hours before blood sampling.)
Specific to the CGM Substudy 10. Is willing and able to wear the CGM device continuously for 14 days to capture measures for baseline CGM assessment (from Week –2 to Week 0) and again for two 14-day intervals during the treatment period (ie, from Week 12 to Week 14 and from Week 22 to Week 24). |
|
E.4 | Principal exclusion criteria |
Patients meeting any of the following criteria will be excluded from the trial: 1. Has initiated treatment with potential novel therapies like dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA. 2. Has a body mass index (BMI)* >45 kg/m² during the screening period. *Body weight and height will be recorded during the screening period for the calculation of BMI (BMI = weight [kg]/[height (m)]2). 3. Has a history of hypoglycemia unawareness (defined as the onset of neuroglycopenia before the appearance of autonomic warning symptoms [eg, blurred vision, difficulty speaking, feeling faint, difficulty thinking, and confusion] or as the failure to sense a significant fall in blood glucose below normal levels). 4. Has a history of 2 or more episodes of severe hypoglycemia and/or 2 or more episodes of diabetic ketoacidosis within the 6 months before the day of screening. 5. Has been exposed to other investigational drug(s) within 1 month or 5 half-lives from screening, whichever is longer.
Specific to the CGM Substudy 6. Uses substances known to interfere with CGM readings, such as aspirin-containing products (>650 mg/day of acetylsalicylic acid) or supplements containing vitamin C (>1000 mg/day of ascorbic acid) taken during the 14-day periods of baseline CGM assessment (ie, from Week –2 to Week 0) and the treatment period (ie, from Week 12 to Week 14 and from Week 22 to Week 24). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
HbA1c: Change from baseline to Week 24 (Gla-300 vs IDeg-100) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Fasting plasma glucose (FPG): Change from baseline to Week 24 • Fasting SMPG: Change from baseline to Week 24 • 7-point SMPG profiles: Change from baseline to Week 24, per time point within 24-hour period • Percentage (%) of patients reaching HbA1c target of <7.0% at Week 24 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 28 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
United States |
Serbia |
Czechia |
Hungary |
Poland |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 18 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |